All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ibritumomab tiuxetan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chelating agents	4984	206181-63-7

Description:

Molecule	Description
Synonyms: ibritumomab tiuxetan (90Y) ibritumomab tiuxetan zevalin IDEC-Y2B8	90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma Molecular weight: 660.50 Formula: C23H32N5O10SY CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 16, 2004	EMA
Feb. 19, 2002	FDA	SPECTRUM PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	95.15	37.21	49	1058	127624	50476393
Bone marrow failure	88.15	37.21	30	1077	27594	50576423
Progressive multifocal leukoencephalopathy	76.91	37.21	22	1085	11435	50592582
Stem cell transplant	69.42	37.21	14	1093	1654	50602363
Myelodysplastic syndrome	66.68	37.21	21	1086	15111	50588906
Neutropenia	47.27	37.21	33	1074	147932	50456085
Enterococcal infection	40.73	37.21	12	1095	6886	50597131
Pancytopenia	39.73	37.21	24	1083	84006	50520011

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelodysplastic syndrome	90.97	35.40	34	1452	17760	29555281
Meningitis tuberculous	77.64	35.40	15	1471	610	29572431
Venoocclusive liver disease	53.50	35.40	18	1468	6899	29566142
Mucosal inflammation	51.32	35.40	27	1459	31568	29541473
Acute myeloid leukaemia	44.60	35.40	20	1466	16493	29556548
Bone marrow failure	43.26	35.40	23	1463	27426	29545615
Herpes simplex	42.91	35.40	14	1472	4876	29568165
Progressive multifocal leukoencephalopathy	42.09	35.40	16	1470	8703	29564338
Thrombocytopenia	39.99	35.40	41	1445	134782	29438259
Stem cell transplant	36.20	35.40	10	1476	1977	29571064
White blood cell count decreased	35.48	35.40	31	1455	83331	29489710

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelodysplastic syndrome	130.50	32.13	47	2553	27532	64468600
Bone marrow failure	108.53	32.13	48	2552	47904	64448228
Progressive multifocal leukoencephalopathy	97.32	32.13	34	2566	18198	64477934
Thrombocytopenia	93.71	32.13	75	2525	223726	64272406
Stem cell transplant	89.44	32.13	22	2578	3459	64492673
Cytomegalovirus infection	67.62	32.13	32	2568	37167	64458965
Meningitis tuberculous	66.51	32.13	14	2586	1097	64495035
Neutropenia	61.59	32.13	61	2539	239563	64256569
Platelet count decreased	61.25	32.13	52	2548	167659	64328473
Pancytopenia	59.75	32.13	48	2552	143261	64352871
Acute graft versus host disease in intestine	59.40	32.13	16	2584	3593	64492539
White blood cell count decreased	57.74	32.13	49	2551	157788	64338344
Acute myeloid leukaemia	51.04	32.13	24	2576	27439	64468693
Multiple organ dysfunction syndrome	51.03	32.13	38	2562	101375	64394757
Acute graft versus host disease in skin	49.26	32.13	16	2584	6839	64489293
Venoocclusive liver disease	47.04	32.13	17	2583	9998	64486134
Mucosal inflammation	42.04	32.13	28	2572	62556	64433576
Respiratory failure	39.41	32.13	40	2560	161143	64334989
Herpes simplex	38.93	32.13	15	2585	10521	64485611
Disease progression	38.03	32.13	37	2563	141643	64354489
Aplasia	37.19	32.13	13	2587	6940	64489192
Enterococcal infection	34.95	32.13	15	2585	13851	64482281
Sepsis	33.97	32.13	44	2556	230297	64265835
Neutrophil count decreased	32.41	32.13	26	2574	77170	64418962

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V10XX02	VARIOUS THERAPEUTIC RADIOPHARMACEUTICALS OTHER THERAPEUTIC RADIOPHARMACEUTICALS Various therapeutic radiopharmaceuticals
FDA MoA	N0000000205	Radiopharmaceutical Activity
FDA MoA	N0000175078	CD20-directed Antibody Interactions
FDA EPC	N0000175658	CD20-directed Radiotherapeutic Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Follicular non-Hodgkin's lymphoma	indication	308121000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD20	Surface antigen	P11836	CD20_HUMAN	ANTIBODY BINDING	Kd	7.85		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D04489	KEGG_DRUG
4021301	VUID
N0000148737	NUI
4021301	VANDF
CHEMBL2108667	ChEMBL_ID
CHEMBL1201606	ChEMBL_ID
C422802	MESH_SUPPLEMENTAL_RECORD_UI
6777	IUPHAR_LIGAND_ID
7873	INN_ID
DB00078	DRUGBANK_ID
4Q52C550XK	UNII
262323	RXNORM
17128	MMSL
d04845	MMSL
385546007	SNOMEDCT_US
385548008	SNOMEDCT_US
C0877880	UMLSCUI
009576	NDDF

Pharmaceutical products:

None